PATENT CLAIM ANALYSIS

Application Number: 15983423
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-10
Patent Classification: ["514", "212070"]

Abstract:
The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

Claim (Index 31):
The compound of  claim 30 , wherein PG is a 4-methoxy benzyl group or a carboxybenzyl group.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 93.0
- Lexical Diversity: 1.6087
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14436152', '14436145', '13506509', '13506510', '13509442']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8645305217255255
- 35 USC 102 Novelty (BERT): 0.6091906320163499
- Combined Prediction Score: 0.838996532754608
- Mean Citation Score: 565.8482339999998
- Max Citation Score: 663.3793
- Similarity Product: 462.0864674717724

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test